Potential cardiovascular effects of incretin-based therapies. - Wikidata - thesis-toulmin - TriplyDB

Potential cardiovascular effects of incretin-based therapies.

Potential cardiovascular effects of incretin-based therapies.

http://www.wikidata.org/entity/Q37990619

about

Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study.Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.Sitagliptin Modulates the Electrical and Mechanical Characteristics of Pulmonary Vein and Atrium.Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.Do we know the true mechanism of action of the DPP-4 inhibitors?Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies.[Modern antihyperglycaemic agents--what is the patient benefit?].

P2860

Q33785146-4ECB2EF0-7309-415E-91D5-84CF3C19C2B5 Q34963221-7364DD66-44BF-4BFF-AB61-502DA8EFD566 Q36649277-BD574EC7-95C2-446C-80D6-D4462C8F4E9F Q36721264-82A07969-C0E9-4751-B48E-DFD49648FE81 Q38014516-49CCC412-DD21-4ED6-A804-12951E122D08 Q38126945-B49F8346-D6FD-4F6B-9922-90ED246D958C Q39329866-1B67AB1B-4EA3-4E90-B5AB-F3D702904ED3 Q41966262-71A3CD4C-BF4C-4529-ADE7-E18B94448C1F Q53790237-34521DB7-A65A-4632-BF3D-86B57D20AFDC

P2860

Potential cardiovascular effects of incretin-based therapies.

http://www.wikidata.org/entity/Q37990619

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Potential cardiovascular effects of incretin-based therapies.

@en

Potential cardiovascular effects of incretin-based therapies.

@nl

type

label

Potential cardiovascular effects of incretin-based therapies.

@en

Potential cardiovascular effects of incretin-based therapies.

@nl

prefLabel

Potential cardiovascular effects of incretin-based therapies.

@en

Potential cardiovascular effects of incretin-based therapies.

@nl

P1433

Q37990619-334FE14A-2971-48B1-AE57-ADC6B655DBE2

P1476

Q37990619-4725B233-668E-4B41-9E7B-7C330D2B1A26

P2093

Q37990619-AAB3C43A-46F5-4ABB-B78E-86FE56145AB5

Q37990619-BE15850D-4705-4216-BB14-3FB31EFDB936

P2860

Q37990619-00C1B98F-7FA1-410F-A438-1320E3449F5E

Q37990619-02A340A3-0CE9-4738-94C3-3BAF250D4A7E

Q37990619-02EDB371-4DDE-4F14-9C5D-893D4987AD28

Q37990619-03FE5862-4028-494B-B782-D17CEC98C9A6

Q37990619-0401132F-25EB-43B8-9EE0-BEF5D2E1157A

Q37990619-0672F6CD-ECD7-4CA8-8581-169E0E837401

Q37990619-0888E3D7-13C0-4322-9D64-EA8D8F04B9A9

Q37990619-09463C1D-C0BE-4C8F-8DBC-E321FA6EAB85

Q37990619-098BA087-4581-492E-9B48-9B44FC7058CF

Q37990619-0C487825-EAD7-4B6E-97F5-4249FE518E15

P304

Q37990619-F8BEBBF6-9526-4886-BAB2-C9FF6BB85F8A

P31

Q37990619-07C4D9DF-5AE9-41FD-B10B-4986665089F7

P356

Q37990619-DA78E3E7-36A1-464B-9843-DA55E071D202

P433

Q37990619-384B5F66-B489-434A-A05A-D9F9F9EFC7D5

P478

Q37990619-D074CE01-815A-43E4-9483-4E398AD2DFA3

P577

Q37990619-614BC81C-CBBC-49B7-A420-F6B9CD6028AC

P698

Q37990619-78C7848F-EA16-44AA-B3E7-63F46E016D0D

P921

Q37990619-BEDCCB16-0155-4355-BB4A-0DCDCA4316CE

P356

P1433

Expert Review of Cardiovascular Therapy

P1476

Potential cardiovascular effects of incretin-based therapies.

@en

P2093

Carolyn F Deacon

http://www.w3.org/2001/XMLSchema#string

Nikolaus Marx

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences

Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

Effects of intensive glucose lowering in type 2 diabetes

Biology of incretins: GLP-1 and GIP

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Glucose control and vascular complications in veterans with type 2 diabetes

Role of smooth muscle cells in the initiation and early progression of atherosclerosis.

P304

337-351

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERC.12.5

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22390806

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio